IRIS
SORRENTINO, Dario Rosario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.917
EU - Europa 1.859
AS - Asia 576
Continente sconosciuto - Info sul continente non disponibili 10
AF - Africa 2
SA - Sud America 1
Totale 11.365
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.872
UA - Ucraina 767
CN - Cina 410
DE - Germania 306
FI - Finlandia 207
SE - Svezia 182
IE - Irlanda 139
IT - Italia 126
TR - Turchia 85
CA - Canada 41
GB - Regno Unito 40
VN - Vietnam 36
FR - Francia 30
NL - Olanda 24
IN - India 18
BE - Belgio 13
IR - Iran 12
EU - Europa 10
PL - Polonia 8
SG - Singapore 8
RU - Federazione Russa 6
CH - Svizzera 4
MX - Messico 4
CZ - Repubblica Ceca 3
HK - Hong Kong 2
IL - Israele 2
AT - Austria 1
CL - Cile 1
ES - Italia 1
JP - Giappone 1
KR - Corea 1
PT - Portogallo 1
RO - Romania 1
TG - Togo 1
TN - Tunisia 1
TW - Taiwan 1
Totale 11.365
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.394
Fairfield 1.206
Houston 818
Ann Arbor 640
Ashburn 551
Seattle 504
Jacksonville 499
Chandler 496
Wilmington 467
Dearborn 417
Cambridge 406
Beijing 156
Princeton 146
Dublin 138
Izmir 85
San Diego 69
Roanoke 61
Udine 54
Des Moines 43
Boardman 40
Nanjing 38
Hefei 37
Dong Ket 36
Kunming 30
Ottawa 29
Norwalk 28
Ogden 28
Jinan 24
New York 16
Guangzhou 15
Nanchang 15
Redmond 15
Torre Del Greco 13
Andover 12
Brussels 12
Falls Church 12
Grafing 11
Helsinki 10
Toronto 10
Redwood City 9
Warsaw 8
Rosendaal 7
Simi Valley 7
Changsha 6
Fuzhou 6
Monmouth Junction 6
Quzhou 6
Shenyang 6
Washington 6
Hebei 5
Leawood 5
Maserada Sul Piave 5
Ningbo 5
Phoenix 5
Singapore 5
Agugliano 4
Baotou 4
Chengdu 4
Chongqing 4
Milan 4
San Mateo 4
Trieste 4
Wenzhou 4
Wuhan 4
Zhengzhou 4
Augusta 3
Fremont 3
Kish 3
Mumbai 3
Sacramento 3
Shanghai 3
Taizhou 3
Zurich 3
Brno 2
Hadera 2
Hangzhou 2
Hong Kong 2
Hyderabad 2
Imperia 2
Jinhua 2
Mexico 2
Mirano 2
Padova 2
Paris 2
Rome 2
Rozendaal 2
Saint Petersburg 2
Shaoxing 2
Shenzhen 2
Silea 2
Tappahannock 2
Tavagnacco 2
Treviso 2
Ürümqi 2
Apo 1
Ardabil 1
Birmingham 1
Bucharest 1
Buffalo 1
Cagliari 1
Totale 8.790
Salva come PNG Salva come JPEG
Nome #
Cavernous transformation of the portal vein associated to multiorgan developmental abnormalities 167
Letter: when to withhold anti-TNF agents prior to abdominal surgery in patients with Crohn's disease—the jury might still be out 161
Postoperative recurrence of Crohn's disease: the beginning of the end? 135
Gastric B-cell clonal expansion and Helicobacter pylori infection in patients with autoimmune diseases and with dyspepsia. A follow-up study. 133
Hepatocellular fatty acid uptake is mediated by a plasma membrane fatty acid binding protein closely related to mitochondrial glutamic oxaloacetic transaminase. 132
Functional and morphological features of isolated hepatocytes preserved in University of Wisconsin solution. 131
"Albumin Receptor" uptake kinetics do not require an intact lobular architecture and are not specific for albumin 130
Prevention of postoperative recurrence of Crohn's disease: does the type of surgery matter? 130
Bringing Top-End Endoscopy to Regional Australia: Hurdles and Benefits 128
B-cell clonal expansion in gastric biopsies of patients with dyspepsia and autoimmune diseases: effect of H. Pylori eradication. 126
Infliximab for postsurgical endoscopic recurrence of Crohn's disease: no trumpets yet 126
Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus 125
Hepatocellular 22Na+ uptake: effect-of-oleate 121
Anti-TNFs for prevention of postoperative recurrence of Crohn's disease: a broken record? 121
Low dose infliximab for prevention of postoperative recurrence of crohn's disease: Long term follow-up and impact of infliximab trough levels and antibodies to infliximab 121
Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease 121
Anti-TNF's for Postoperative Recurrence in Crohn's Disease: The If's and How's 120
Impact of Diagnostic Delay and Associated Factors on Clinical Outcomes in a U.S. Inflammatory Bowel Disease Cohort 119
Uptake of oleate by isolated rat adipocytes is mediated by a 40 kDa plasma membrane fatty acid binding protein closely related to that in liver and gut 117
The hepatocellular transport of sulfobromophthalein-glutathione by clofibrate treated, perfused rat liver 115
Acute severe colitis: infliximab and/or cyclosporine? 115
Oleate uptake by isolated hepatocytes and the perfused rat liver is competitively inhibited by palmitate 115
Transferrin metabolism in alcoholic liver disease. 114
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease after Ileocolonic Resection 112
Plasma membrane fatty acid-binding protein and mitochondrial glutamic-oxaloacetic transaminase of rat liver are related 112
At physiologic albumin:oleate concentrations oleate uptake by isolated hepatocytes, adipocytes and cardiac myocytes is a saturable function of unbound oleate concentrations. Uptake kinetics are consistent with the conventional theory 110
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease 110
Diagnosis and assessment of Crohn's disease: the present and the future 109
Ustekinumab as induction and maintenance therapy for ulcerative colitis 109
B cell clonality in gastric lymphoid tissues of patients with Sjogren's syndrome 108
Mechanistic aspects of hepatic bilirubin uptake 108
Sex differences in hepatic fatty acid uptake reflect a greater affinity of the transport system in females 108
Surgery for Crohn's disease and anti-TNF agents. The changing scenario 107
B-cell clonality and infection with Helicobacter pylori: implications for development of gastric lymphoma 107
Infliximab in Crohn's disease: a look at the (not so distant) future. 106
Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome 105
Transmembrane TNF-α density, but not soluble TNF-α level, is associated with primary response to infliximab in inflammatory bowel disease 105
Ustekinumab as induction and maintenance therapy for Crohn's disease 105
Isolated Bilateral Gastrocnemius Myositis in Crohn Disease Successfully Treated with Adalimumab 105
Fibrocytes, Inflammation, and Fibrosis in Crohn's Disease: Another Piece of the Puzzle. 104
Therapeutic Targets in Inflammatory Bowel Disease: Are We Getting the Point Across? 104
Prevention of postoperative recurrence of Crohn's disease by infliximab 104
Bile acid secretion and pool size during phenobarbital-induced hypercholeresis 103
Phenobarbital specifically increases the hepatocellular uptake of sulfobromophthalein-glutathione. 103
Hepatic disposition of clinically useful 5-nitrofurans 102
Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? 102
Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease 101
An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients 101
Characteristics of oleate binding to liver plasma membranes and its uptake by isolated hepatocytes 100
Isolation and partial characterization of plasma membrane fatty acid binding proteins from myocardium and adipose tissue and their relationship to analogous proteins in liver and gut 99
Unbound ligand drives hepatocyte taurocholate and BSP uptake at physiological albumin concentration 99
The race for mainstream gastrointestinal endoscopy: frontrunners. 98
The hepatocellular uptake of free fatty acids is selectively preserved during starvation 97
The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease. 97
Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents 97
Organic anion-transporting polypeptides: expression cloning and functional tests 95
Quantitation of plasma membrane fatty acid binding protein by enzyme dilution and monoclonal antibody based immunoassay 94
Familial hyperbilirubinaemia syndromes: kinetic approaches 94
Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. 94
Esophageal ulceration due to alendronate 93
Small Bowel Inflammation in Crohn's Disease and Other Conditions 93
Scientific publications in gastroenterology and hepatology in Western Europe, USA and Japan in the years 1992-1996: a global survey 93
"Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy 92
Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis 92
Microbial dysbiosis in spouses of ulcerative colitis patients: Any clues to disease pathogenesis? 92
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. 90
Mechanisms of cellular uptake of free fatty acids 90
Adipocyte differentiation of 3T3-L1 cells involves augmented expression of a 43 kDa plasma membrane fatty acid binding protein 89
Continuous monitoring of the biliary excretion of a pulse of labeled compounds 88
Heart-touching Chilaiditi's syndrome 88
Utility of fecal markers to diagnose and monitor inflammatory bowel diseases 88
Diagnostic and Therapeutic Delays in the Management of Postoperative Crohn's Disease 88
Colonic sarcoidosis, infliximab, and tuberculosis: a cautionary tale 87
Clinically Significant Small Bowel Crohn's Disease Might Only be Detected by Capsule Endoscopy 87
Unexplained Symptoms and Hidden Inflammation in Patients With Crohn's Disease 87
Helicobacter pylori infection and autoimmune processes: an emerging field of study. 85
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. 85
Internet use among inflammatory bowel disease patients: an Italian multicenter survey. 85
Oleate uptake kinetics in the perfused rat liver are consistent with pseudofacilitation by albumin 85
Characterization of prelymphomatous stages of lymphoproliferation in Sjögren’s syndrome. 85
Hepatocellular sulfobromophthalein uptake at physiologic albumin concentrations: Kinetic evidence for a high affinity/low capacity sinusoidal membrane system 84
Clinical remission after stopping infliximab in Crohn's disease: is all that glitters true gold? 82
Long-term prevention of postoperative Crohn's disease recurrence with azathioprine: the wolf in the sheep clothing. 80
Gastric B-cell clonal expansion and hepatitis C virus infection: a study in patients with Sjögren’s syndrome. 77
MRI scoring system including dynamic motility evaluation in assessing the activity of Crohn's disease of the terminal ileum 77
B-cell clonality in gastric mucosa of patients with Sjögren's syndrome and connective tissue diseases: relationship with Helicobacter pylori, EBV and human herpesvirus-6 (HHV-6) infections. 74
The hepatocellular uptake of bilirubin: current concepts and controversies. 74
Risk of combining immunosuppressive and biological treatments in inflammatory bowel disease 74
Medical prevention of postoperative recurrence of Crohn’s Disease: The state of the art 73
The Coming of Age of Inflammatory Bowel Diseases in Asia 73
Hepatitis C virus infection and gastric lymphoproliferation in patients with Sjögren's syndrome 71
B-CELL CLONAL EXPANSION IN GASTRIC BIOPSIES OF PATIENTS WITH DYSPEPSIA AND AUTOIMMUNE-DISEASES - EFFECT OF HELICOBACTER-PYLORI ERADICATION 71
Early Diagnosis and Treatment of Postoperative Endoscopic Recurrence of Crohn's Disease: Partial Benefit by Infliximab-A Pilot Study 71
Gastric lymphoid follicles: prevalence in patients with dyspepsia and with autoimmune diseases and relationship with Helicobacter pylori infection. Gastroenterology 70
Management of post-operative Crohn’s disease in 2017: where do we go from here? 69
From albumin to the cytoplasm: the hepatic uptake of organic anions 68
Knowledge Gaps in the Management of Postoperative Crohn’s Disease: A US National Survey 68
235) La terapia con Infliximab più Metotrexate a basse dosi nella prevenzione delle recidive post-chirurgiche del Morbo diCrohn 67
Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link 65
Low-dose biologics to treat inflammatory bowel disease. Ready for prime time? 64
Totale 9.951
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.310
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.310
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.509 177 171 129 504 264 574 482 370 284 258 79 217
2020/20211.853 38 247 153 213 67 208 93 206 229 68 204 127
2021/20221.177 49 120 51 85 35 57 73 62 12 201 216 216
2022/20231.193 165 79 14 136 116 368 10 69 163 13 20 40
2023/2024276 51 29 12 2 50 50 4 21 38 2 7 10
2024/20255 5 0 0 0 0 0 0 0 0 0 0 0
Totale 11.761